Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. - Test2 - elhamkhani - TriplyDB

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.

http://www.wikidata.org/entity/Q33610598

about

Abl family kinases regulate endothelial barrier function in vitro and in mice A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation.Neuroimmunological blood brain barrier opening in experimental cerebral malaria Rat models of spinal cord injury: from pathology to potential therapies Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability Imatinib enhances functional outcome after spinal cord injury Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilization Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.Where will the next generation of stroke treatments come from?Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.Exploiting the promiscuity of imatinib.Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse Platelet-derived growth factor (PDGF)-C inhibits neuroretinal apoptosis in a murine model of focal retinal degeneration.Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin.Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass.Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation.The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets.Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats VEGF-independent angiogenic pathways induced by PDGF-C.NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration.Improving low-dose blood-brain barrier permeability quantification using sparse high-dose induced prior for Patlak model.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.

P2860

Q24316240-2E59E626-FB92-4A73-97E5-CCFA49518156 Q26772837-7B29E09D-2D80-44B4-8EE5-01603FD66E54 Q26777274-B4614700-C19D-4224-916C-C5DE99E9E1C3 Q26777276-CB389135-F751-44E4-9D90-62620874384B Q26781646-B250B47F-2220-47FA-9D7D-5C43929EA4C6 Q26852944-AD5CEF76-D3E1-40DB-979F-A4BAF0DC0800 Q27319705-5B6246AC-B584-4371-8561-81CF2EF2CE38 Q27341951-F96D59C7-53C5-45CC-A82F-E106A88CD470 Q28071816-B859130A-46ED-4672-89F5-2AA680354013 Q28478866-5E9606F4-F7CA-41C0-AFB3-B09C221036A9 Q28480537-2C1B9D5D-A125-4A2A-A759-001B2748B073 Q28587728-82E6419C-88B3-4838-A83B-B105E1CE33C2 Q28593367-92A75726-2F47-4D74-AAA2-0DFEFC5E2235 Q29048615-1B4501B7-4CE1-4623-A6B0-65748EEC9389 Q30528502-46F5D940-99C4-4121-90C2-D808CEAD2DDC Q30563965-20F3E91A-29B3-4ABF-A786-90A4419D8E35 Q30746065-E5726F14-8C59-4120-A76C-A92F71922A59 Q30979218-06E71BBC-8436-4EF2-9B32-24CC6AD4094D Q33369942-68A8A967-7056-48F4-8882-70A568D2E7B2 Q33389941-94FBA291-ABD6-4311-9CBE-DD9EEC01843C Q33427833-73CB3961-870A-4C1D-A590-9ADC1B358FAB Q33444245-39DDABE6-CECB-40E3-B5CC-BDBDA5F65325 Q33530141-7B072B61-FA43-4239-95E2-8805115343AF Q33690414-99D924A3-3CF9-472B-AB47-11B94F0504E2 Q33693655-78A6EE11-8776-4C98-8BAD-3BA6F314F6FC Q33711943-027562C2-97DE-4E2A-9543-ACE844C79A35 Q33782785-C29FC3FB-4092-447E-9B6E-FB0C79328323 Q33794983-CD4CF02B-9CBE-4D4F-84E5-B8AC22BF67CA Q33823616-C66CD5B0-70EC-40C0-A91C-45CF8D072DE1 Q33827436-711E3F7F-C362-44E0-BC3D-BF7C0D11025E Q33924274-143BE346-71EC-425D-87FF-54B482C13D7E Q33981871-E66C2B5C-9E49-4D52-BEF0-7D050E428E3D Q34006140-04AFFFE0-B6E5-4246-A347-98FA3D3F7C5B Q34018715-B74BD6CC-64EC-4305-BEB5-5B8C074B4E00 Q34028825-92163F33-0B5E-467F-9DE9-18A79C2B9F9B Q34074200-085889C4-119B-45BF-B5D6-742DF187C144 Q34149273-90D15FB1-F6C0-4906-86FE-137B37AA6F81 Q34150884-41720C65-50FB-46EF-B159-526989381BC5 Q34300902-AC9A4774-05BC-4916-99F2-DBCD53BDB396 Q34352802-F6FBF64D-B3C6-4B41-AF91-03312F896702

P2860

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.

http://www.wikidata.org/entity/Q33610598

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@ast

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@en

type

label

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@ast

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@en

prefLabel

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@ast

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@en

P1433

Q33610598-8A327E2E-5398-4114-B558-E66778318BC4

P1476

Q33610598-CCDAADB7-8103-4FAF-AADB-3FBB92F515F5

P2093

Q33610598-1EE8BC52-A4B8-44C0-B541-8C5E4B3CEB92

Q33610598-22A113CA-52A6-4EB6-B744-55E46107AEB9

Q33610598-2B53F762-EB64-4C70-AEB3-88BB8B9326F6

Q33610598-5CDEA2D0-EA23-4423-B5EA-F2EC86A77EBA

Q33610598-5F67CE7B-F9AF-46A6-B20D-65828DB78474

Q33610598-81E37AFB-EA5B-4826-95B4-962535F6B6B1

Q33610598-83B83880-4752-455C-8C83-37151466E0F3

Q33610598-B48A44B3-3231-42F1-8B21-4AB1FC2A5FAF

Q33610598-DB987B65-8F62-4618-A87D-8A73D212A985

Q33610598-E122CBEB-A34B-4768-9350-190CB430DE62

P2860

Q33610598-06769E5D-0C64-46A0-9F4A-772AA05ACA03

Q33610598-12044EA1-A284-4D6B-B2D4-9D4E4A97DCB9

Q33610598-138B895E-5F72-4156-A782-AF36B632A024

Q33610598-14CD5C0C-F938-4336-98F4-E43D9B653F50

Q33610598-1BD86072-64DD-4366-B18E-125F24B1739D

Q33610598-2287FC9C-5CC5-4699-8DD1-BF61D6B6BD9E

Q33610598-2A837DD0-A7CE-4D15-8FB0-F86BCDBB68B1

Q33610598-2F58C779-43E8-484F-A30A-7CDB0361D16D

Q33610598-30418BE2-9304-48DE-829B-794E9BBCE0C7

Q33610598-3EECE499-C0D4-4102-9FFB-4076C8A22FD7

P2888

Q33610598-EC351B49-B8B4-4922-9AFB-DCE524E63BD2

P304

Q33610598-6E70545E-0EE1-4EEC-9F5A-16FFC337F1A3

P31

Q33610598-5B8D416A-3C9A-4276-B34B-C73AB3487139

P356

Q33610598-1E123483-3E4C-4772-BA34-1CF5039DEB93

P407

Q33610598-AEF810F3-B8EE-4377-8199-EF43D2B9C3CD

P433

Q33610598-BF6B8838-09FC-4D63-BC90-44749A93CB65

P478

Q33610598-16BB9341-F429-4925-9A6F-D15251FE7BAD

P50

Q33610598-E8C10E2C-25FA-4EDA-9FF6-D52B83D599A5

P577

Q33610598-897C427F-BFF7-4FFC-91F9-5ED285D3DE40

P5875

Q33610598-9EB8C021-3134-4C58-AB00-F2FAB458C50D

P6179

Q33610598-270A5267-DA62-44C8-ACAB-59DC408F1418

P698

Q33610598-5600C4DD-CCA3-407A-90B0-91FE632A242C

P921

Q33610598-BB8CA265-4CC9-4C5E-95B1-845A7B7C4009

P932

Q33610598-077F677F-F68D-41CA-8AB9-2A5F7ACFDCE7

P356

P1433

Nature Medicine

P1476

Activation of PDGF-CC by tissu ...... egrity during ischemic stroke.

@en

P2093

Daniel A Lawrence

http://www.w3.org/2001/XMLSchema#string

Dudley K Strickland

http://www.w3.org/2001/XMLSchema#string

Enming J Su

http://www.w3.org/2001/XMLSchema#string

Erika Folestad

http://www.w3.org/2001/XMLSchema#string

Jacqueline Cale

http://www.w3.org/2001/XMLSchema#string

Johanna Andrae

http://www.w3.org/2001/XMLSchema#string

Kris Mann

http://www.w3.org/2001/XMLSchema#string

Kristian Pietras

http://www.w3.org/2001/XMLSchema#string

Linda Fredriksson

http://www.w3.org/2001/XMLSchema#string

Manuel Yepes

http://www.w3.org/2001/XMLSchema#string

P2860

PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)

Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent

A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling

Tissue plasminogen activator is a potent activator of PDGF-CC

Tissue plasminogen activator for acute ischemic stroke

Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain.

The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors.

Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation.

P2888

P304

731-737

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1787

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Christer Betsholtz

P577

2008-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5288618

http://www.w3.org/2001/XMLSchema#string

P6179

1008928769

http://www.w3.org/2001/XMLSchema#string

P698

18568034

http://www.w3.org/2001/XMLSchema#string

P921

blood–brain barrier

P932

2811427

http://www.w3.org/2001/XMLSchema#string